Importantly, the TATTON study was conducted to evaluate the safety and tolerability of osimertinib combined with selumetinib (MEK1/2 inhibitor), savolitinib (MET inhibitor), or durvalumab (anti-PD-L1 monoclonal antibody) in advanced EGFR-mutant NSCLC patients who progressed on a prior EGFR-TKI [134]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.